Direct answer. Pharmaceutical businesses in the UK and India grow with AI, automation and custom software when the batch or the pack, the quality result, the live shortage or clearance, and the person who may release or supply sit on one release file. The file shows which batch is still waiting, which shortage protocol can still change, and who accepted the next release, hold, supply or notice. Cogitix builds that file beside the systems already in use. A person accepts or stops the line before another pack moves. This article does not invent a savings percentage. Cogitix does not manufacture, test, release or dispense a medicine.
The examples are patterns, not client stories. Cogitix is an AI agency that builds software for clients worldwide. It does not clear a solvent, file a regulatory notice, or decide that a medicine is safe to supply.
What file is checked before a release, a supply or a notice moves?
A batch record, a wholesaler status and a dispensing screen already exist. When they stay apart, the next batch can move while a quality result is open, or a pharmacy can supply against a protocol that has been amended. Before the next release, hold, supply or notice, the release file stores the batch or the presentation, the quality status, the shortage or clearance status, any open complaint or recall, and who accepted the next step. A gap is "not known" or "not received". Waiting is an honest status. It is not a certificate that the medicine meets its specification.
Why does a split quality and shortage record hurt supply?
In England, the notice and the counter often disagree about the same medicine. GOV.UK says manufacturers must notify the Department of Health and Social Care of shortages and discontinuations that meet the reporting criteria, through the DaSH portal. Healthcare professionals then hear about it through a medicine supply notification and the NHS medicines supply tool. A serious shortage protocol, where one is issued, is published by the NHS Business Services Authority. Community Pharmacy England, updated on 15 October 2026, says its own summaries freeze on the day of issue, so teams should recheck the tool, confirm the protocol is still active, and endorse the claim correctly. Its Pharmacy Pressures Survey 2026 reported that 86 percent of pharmacies are spending longer procuring medicines than last year. That is a sector reading, not a timing target for one counter.
Two live cases show why the end date has to sit on the pack. Community Pharmacy England on 9 September 2026 reported SSP088 and SSP089 for lansoprazole orodispersible tablets: one month where the prescription is longer, the prescriber notified, the protocol number endorsed, expiry 15 January 2027 unless amended. It said many claims are still rejected for a wrong endorsement, and cited a £1.52 single activity fee and a £5.35 protocol fee. Olivier Picard of the National Pharmacy Association, also reported by The Pharmacist the next day, put lansoprazole with ramipril, aspirin, co-codamol and Creon. MIMS on 3 November 2026 reported Norzyme available while the Creon 25,000 protocol, in place since May 2024 and extended to January 2027, remains, with limited stock expected until the end of April 2027. Citing an earlier survey, MIMS said 96 percent of 300 pharmacies had trouble supplying Creon. The tracker was updated on 6 November 2026. The file stores the live protocol, the endorsement and whether the prescriber was told. It does not choose a substitute.
India's version is a batch that can still move while the quality record is incomplete. The Economic Times on 3 June 2026 reported Pharmexcil's estimate that only 25 to 40 percent of nearly 8,500 small and medium units are fully or near-compliant with revised Schedule M. The paper described the revision as covering documentation, data integrity, complaints and recalls from December 2025. Akshansh Chaudhary of Venus Remedies cited upgrades of Rs 10 to 15 crore a facility and more than 60 percent of units at risk. Those figures are the paper's, not a budget for one site.
This month the same gap became a licence question. On 4 November 2026 the Press Information Bureau published a draft that would suspend a manufacturing licence immediately when a Government Analyst declares a drug not of standard quality for assay, dissolution, related substances, impurities or sterility, until corrective action is verified. The Bureau said today's show-cause step can leave the medicine in circulation. The draft is open for 30 days and is not yet the rule. The Hindu BusinessLine on 5 November 2026 carried the same proposal. On 8 November 2026 Medical Dialogues, reporting Business Standard, said named solvents, including glycerin and propylene glycol, need a batch no-objection certificate before distribution. The report links that scrutiny to Coldrif, associated with the deaths of 24 children in Madhya Pradesh in 2025. The file stores whether the certificate and the quality status are present, waiting, or not received. It does not test a solvent.
Where should a manufacturer, a wholesaler or a pharmacy start?
Keep the batch system, the pharmacy or wholesale system, and the mailbox that receives notices. Add one record for one manufacturing site, or for one pharmacy if the pain is the counter. In Britain, start with one presentation that has a live protocol or a manufacturer notification still open. In India, start with one batch whose quality parameter, complaint, recall or solvent certificate is not yet on the same line as the person who may release it. Each line has a source, a date, and a status of known, open, not received or waiting. Start that join with digital transformation consulting. A related patient-record pattern is in the healthcare guide. Cogitix does not run a clinic.
How do four steps connect the batch, the notice and the person?
1. Build one live release file
Write the batch or the presentation once: the quality parameter and its status, the shortage or clearance status, any open complaint or recall, and the name of the person who may decide. Missing data is "not received" or "not linked". Build the join with custom web development, a mobile app, or WhatsApp automation when notes already arrive there. The layer reads systems already in place. It does not release a batch or submit a form. Movement of a released pack can follow the logistics guide. Cogitix does not ship the medicine. A plant record of a different kind is in the manufacturing guide.
2. Warn early when a result, a protocol or a clearance will not meet
A draft may flag a parameter still marked not received, a protocol whose end date has passed or changed, a solvent batch whose certificate is waiting, or a manufacturer notification with no send status. It stays a draft until a person accepts it. The software must not invent a test result, treat a score as a release, or mark a notice as filed. That boundary is AI agent integration, as with autonomous agents. The draft is not a batch release and it is not a supply.
3. Join the recall, the prescriber notice and the endorsement before another pack moves
The draft can place the recall status, the prescriber notification and the endorsement on the same presentation before another pack leaves. A quality lead or a superintendent pharmacist accepts, queries or returns that join. The record stores the choice. If the batch record and the public notice disagree, the status stays open. The same checkpoint is in how to improve workflows using AI. A later dispute can use the legal guide. Cogitix does not give legal advice and does not test the batch.
4. Recommend a release, a hold, a supply or a notice, then wait
The draft can list a release, a hold, a supply under a named protocol, or a notification still to send. A person approves, changes or refuses it. The file stores the name and the reason. It does not change the source system and it does not dispense. Plain-language answers for staff who already have access are answer engine optimisation and generative engine optimisation. Several sites on one history is cloud-based SaaS. A workflow another group can run is end-to-end product development. Cogitix does not hold a manufacturing licence.
What is different for manufacturers and pharmacies in the UK?
For one presentation, store whether a protocol is active and the date it runs to, whether the endorsement uses that protocol number, and whether the prescriber was notified. For a marketing authorisation holder, store whether the DaSH notification is sent, still open, or not received. The survey figures above are context, not a target for this pharmacy. A supply or a release waits for the person allowed to make it. Cogitix does not endorse a prescription.
What is different for manufacturers in India?
For one batch, store the parameter, the analyst status if a government report exists, the solvent certificate if that input is covered, and the open corrective action. The Pharmexcil range is the market behind that line, not a spend target. The November licence proposal is still a draft. A person accepts any further manufacture. Cogitix does not suspend a licence or sign a certificate of analysis.
Should you buy, configure, or build?
Buy or configure when the product already stores the batch or presentation, the quality status, the shortage or clearance status, the open recall and the person who accepted the next step, and can hold the release while that status is waiting. Build when one history must hold a British protocol endorsement and an Indian batch certificate, or when a branch note and an analyst report must land on the same product. The business's own person still decides. Cogitix builds the file beside systems already in use. It does not manufacture, test, release or dispense.
What does a 90-day pilot include?
Days 1 to 15. One site or one pharmacy, who may see batch and shortage data, and a rollback if the join is wrong. Days 16 to 45. One team. The next release, supply or notice waits until a person accepts it. Days 46 to 75. Recount lines with no quality status, no shortage or clearance status, or no name on the decision. This guide has no benchmark percentage. Days 76 to 90. Add a second site on its own file, or stop.
How does Cogitix help?
Cogitix is an AI agency. It builds AI agents, AI automation and AI-powered custom software, and it delivers working software quickly for clients worldwide. The canonical site is https://www.cogitix.io/. The public email is hello@cogitix.io. No phone number is published. Hours on the site are Monday to Saturday, 9:00 am to 6:00 pm. Describe one site or one pharmacy, the system that already holds the batch or the prescription, and who may accept a release or a supply, on the contact page. More about the company is on the about page.
Talk through one pharmaceutical release file
Name the site or the pharmacy, the system that already holds the batch or the prescription, and who may accept the next release or supply. Cogitix replies at hello@cogitix.io.
Sources
Sources cited for this article. They are not endorsements of Cogitix, and they are not instructions for manufacturing, testing or dispensing a medicine. Figures below are taken from those sources. This article adds none of its own. Each page linked here was opened. The Sun Pharmaceutical report is cited only as The Hindu BusinessLine reported Reuters. The solvent-clearance account is cited only as Medical Dialogues reported Business Standard. The Creon survey is cited only as MIMS reported the National Pharmacy Association.
- Medicine supply management, Department of Health and Social Care and NHS England, GOV.UK. Manufacturers have a legal obligation to notify DHSC of shortages and discontinuations that meet the reporting criteria, via the DaSH portal. Healthcare professionals are informed through medicine supply notifications and the NHS medicines supply tool hosted by the Specialist Pharmacy Service. Serious shortage protocols are published by NHSBSA. A national patient safety alert may be issued through the MHRA central alerting system. Disruption can arise from raw materials and packaging through compliance testing, certification and last-mile delivery.
- Medicine shortages, Community Pharmacy England, updated 15 October 2026. Teams should check the medicines supply tool because CPE summaries of medicine supply notifications are not updated after issue. Before a supply under a serious shortage protocol, confirm the protocol is active, the patient and prescription meet it, the patient agrees, and the claim is endorsed as required. The Pharmacy Pressures Survey 2026 reported that 86 percent of pharmacies are spending longer procuring medicines than they did last year.
- Two SSPs issued for Lansoprazole 15mg and 30mg orodispersible tablets, Community Pharmacy England, 9 September 2026. SSP088 and SSP089 limit supply to one month where the prescription is longer, may be amended or revoked, and expire on 15 January 2027. The prescriber is notified. Endorsement with SSP088 or SSP089 is required. A large number of claims continue to be deemed invalid because of incorrect endorsements. Fees cited: one single activity fee, currently £1.52, and one SSP fee of £5.35.
- Urgent taskforce needed for medicines shortages, following new SSPs, says pharmacy leader, Cahal McQuillan, The Pharmacist, 10 September 2026. Olivier Picard on lansoprazole joining ramipril, aspirin, co-codamol and Creon, and on a complex supply chain.
- Medicine shortages: NPA responds to Lansoprazole Serious Shortage Protocol, National Pharmacy Association, 9 September 2026. Olivier Picard on concern about lansoprazole, the same list of hard-to-source medicines, and pharmacies describing shortages as the worst they have experienced.
- New pancreatin preparation launched as long-standing Creon shortage continues, Dawn Liz Powell, MIMS, 3 November 2026. Norzyme available while the Creon 25,000 serious shortage protocol, in place since May 2024, was extended in October 2026 until January 2027. Limited stock expected until the end of April 2027. Creon 10,000 protocol expired in October, with normal supply not expected until late April 2027. MIMS's report of an NPA survey: 96 percent of 300 pharmacies facing challenges supplying Creon, and 89 percent reporting difficulties with pancreatin alternatives.
- Drug shortages, MIMS. Shortages tracker updated 6 November 2026, 6:21am. The 3 November 2026 Creon and Norzyme item is listed on the same page.
- Over 60% of pharma MSMEs yet to comply with updated manufacturing norms, Shariq Khan, The Economic Times, 3 June 2026. Pharmexcil estimate: 25 to 40 percent of nearly 8,500 small and medium units fully or near-compliant with revised Schedule M. Comments from Akshansh Chaudhary, Saurabh Agrawal and Namit Joshi on cost, documentation, data integrity, talent and smaller exporters, including the Rs 10 to 15 crore, 35 percent, 67 percent, 4 percent and 20 to 30 percent figures as each speaker gave them.
- Union Health Ministry proposes immediate suspension of manufacturing licences for drugs found not of standard quality on specified critical parameters, Press Information Bureau, 4 November 2026. Draft amendment: immediate suspension where a Government Analyst declares a drug not of standard quality for assay, dissolution, related substances, impurities or sterility, until root-cause analysis and corrective and preventive action are verified. Report to be endorsed to the DCGI, the state or union territory licensing authority, and the manufacturer and marketer. Existing show-cause process can leave the drug in circulation. Comments invited for 30 days. Follows the Drugs Consultative Committee on 20 December 2024 and the Drugs Technical Advisory Board on 24 April 2025.
- India proposes immediate suspension of drug manufacturing licences over quality failures, Reuters, published by The Hindu BusinessLine, updated 5 November 2026. Same draft, described as dated 28 October and published on 4 November. BusinessLine's report that Reuters had reported an order stopping Sun Pharmaceutical Industries from manufacturing, selling and distributing ophthalmic products made at its Assam facility after quality-management failures.
- Pharma industry seeks CDSCO clarity on batch-wise solvent clearance, flags risk of medicine supply disruptions, Parthika Patel, Medical Dialogues, 8 November 2026, reporting Business Standard. Batch-wise no-objection certificates on the Online National Drugs Licensing System before distribution of glycerin, propylene glycol, sorbitol, maltitol, polyethylene glycols, polysorbates and ethyl alcohol. Comments attributed to Rishi Agrawal and Arushi Jain. Coldrif cough syrup, 24 children in Madhya Pradesh in 2025, and diethylene glycol, as that report states them.
Questions about pharmaceutical software with Cogitix
What is Cogitix?
Cogitix, short for Cogitix Tech Solutions, is an AI agency. It builds AI agents, AI automation and AI-powered custom software, and it delivers working software quickly for clients worldwide. The canonical website is https://www.cogitix.io/. The cogitix.in domain is an alias of the same site. The public email is hello@cogitix.io.
What should a UK manufacturer or pharmacy record before a release or a supply?
GOV.UK says manufacturers must notify the Department of Health and Social Care, through the DaSH portal, of shortages and discontinuations that meet the reporting criteria. Community Pharmacy England, updated on 15 October 2026, says its summaries of supply notices are not updated later, and that a supply under a serious shortage protocol needs an active protocol, a matching patient and prescription, the patient's agreement, and a correct endorsement. On 9 September 2026 it reported SSP088 and SSP089 for lansoprazole orodispersible tablets, expiring on 15 January 2027 unless amended, with a single activity fee of £1.52 and a protocol fee of £5.35, and with many claims rejected for a wrong endorsement. MIMS on 3 November 2026 reported Norzyme on the market while the Creon 25,000 protocol, in place since May 2024 and extended to January 2027, remains, with limited stock expected until the end of April 2027. Its report of an earlier NPA survey said 96 percent of 300 pharmacies had trouble supplying Creon. The Pharmacy Pressures Survey 2026 reported that 86 percent of pharmacies are spending longer procuring medicines than last year. Record the presentation, the protocol number and end date, the endorsement, the prescriber notice, the DaSH status if this business must notify, and the person who accepts the supply or the release. This is a reading of those pages, not a dispensing instruction.
What should a manufacturer in India record before another batch moves?
The Economic Times on 3 June 2026 reported Pharmexcil's estimate that 25 to 40 percent of nearly 8,500 small and medium units are fully or near-compliant with revised Schedule M, which the paper described as covering documentation, data integrity, complaints and recalls. On 4 November 2026 the Press Information Bureau published a draft that would suspend a manufacturing licence immediately when a Government Analyst finds a drug not of standard quality for assay, dissolution, related substances, impurities or sterility, until corrective action is verified. The draft is open for 30 days and is not yet the rule. Medical Dialogues on 8 November 2026, reporting Business Standard, described batch-wise no-objection certificates for named solvents before distribution. Record the batch, the parameter, the analyst status if a report exists, the solvent certificate if the input is covered, the open corrective action or recall, and the person who accepts further manufacture. This is a reading of those pages, not a release for one site.
When is custom release-file software a better fit than another AI pilot?
Custom software fits when the batch record, the pharmacy system and the notice mailbox stay separate, when a branch note has to land on the batch, or when a pilot cannot show why this pack is still moving with no quality status and no named decision. A quality suite and a chatbot are enough only while one person can still name the parameter, the protocol and the status without opening every system. Cogitix builds the record beside the systems the business already runs. It does not manufacture the medicine or run the pharmacy.
What should a 90-day pharmaceutical pilot include?
One site or one pharmacy, one team, a rollback, and a human checkpoint before the next release, supply or notice. Recount lines with no quality status, no shortage or clearance status, and decisions with no name. At day 90, add a second site on its own file, or stop. Cogitix does not publish a standard savings percentage, because that number would not describe your batches or your shortages.
Does Cogitix manufacture medicines, release batches, or publish a phone number or a street address?
Cogitix does not manufacture, test, release or dispense medicines, file a regulatory notice, or suspend a licence. The site publishes the email hello@cogitix.io and hours of Monday to Saturday, 9:00 am to 6:00 pm. A telephone number and a street address are not listed. Cogitix serves clients worldwide.
